Introduction
Aberrant activation of receptor tyrosine kinases is a common event in human cancer. 1, 2 Alterations in receptor tyrosine kinase structure, aberrant expression or coexpression with the respective ligand have also been linked with leukemogenesis. [3] [4] [5] Flt3 is a member of the class III receptor tyrosine kinases and related to c-Kit (stem cell factor receptor ) and c-Fms, other important regulators of hematopoiesis. Each of them are composed of five immunoglobulin-like subdomains in the extracellular region. 6 Flt3 plays a role in proliferation and differentiation of B cell progenitors, [7] [8] [9] myelomonocytic and dendritic cells [10] [11] [12] as well as in the maintenance of pluripotent hematopoietic stem cells. 13, 14 Activation of Flt3 by its cognate ligand FL ('Flt3 ligand') leads to receptor autophosphorylation. Further signal transduction is mediated by association of downstream signaling molecules including SHP-2, SHIP, Grb2 and the p85-subunit of PI3Kinase. 15, 16 Flt3 is overexpressed in different types of leukemia, including B-lineage ALL and AML as well as T-ALL and CML blast crisis cells. [17] [18] [19] High expression levels of FL increase the probability of leukemic transformation in Flt3-positive cells. 20 Activating mutations in the Flt3 gene have been detected in AML patients. An internal tandem duplication mutation (ITD) in the Flt3 juxtamembrane domain has been found in approximately 20% of patients and is associated with poor prognosis. [21] [22] [23] [24] [25] The mutated Flt3 protein confers constitutive activation of Stat5 and the Ras-MAP kinase pathway and autonomous growth to IL-3-dependent cell lines. [26] [27] [28] In addition, missense mutations involving Asp835 in the Flt3 activation loop have been found in 7% of AML patients. This type of mutation leads to constitutive kinase activity. 29, 30 Flt3 may, therefore, be a suitable target for therapy of Flt3-dependent leukemias.
Recently, we and others have shown that certain tyrosine kinase inhibitors can block Flt3-dependent growth and transformation. [31] [32] [33] The tyrphostin AG1295/96 family of compounds, originally characterized as selective inhibitors of platelet-derived growth factor (PDGF)␣-and ␤-receptor as well as c-Kit, 34, 35 block Flt3 tyrosine kinase efficiently. 32 On the other hand, Flt3 is not inhibited by the phenylaminopyrimidine CGP57148B/STI571, an inhibitor of Abl, PDGF␣-and ␤-receptor and c-Kit tyrosine kinases 36 which has recently been approved for the treatment of CML. 37 Bis(1H-2-indolyl)-1-methanones are a novel class of tyrosine kinase inhibitors with selectivity for the PDGF receptor family. 38 Here, we show that compounds from this class of tyrosine kinase inhibitors are effective inhibitors of Flt3, block Flt3-dependent transformation and sensitize Flt3-transformed cells for radiationinduced apoptosis.
Materials and methods

Cell lines, DNA constructs and reagents
BA/F3 cells stably transfected and thereby transformed with a TEL-hFlt3 construct were obtained and cultivated as described previously. 28 A constitutively active, membrane-associated variant of Flt3 with a hemagglutinin-tag, designated HA-TELFlt3, will be described elsewhere. BA/F3 cells stably transfected with this construct grow autonomously and have similar properties as TEL-hFlt3-transformed BA/F3 cells (Tse et al, unpublished data The IL-3-dependent murine myeloid cell line 32Dcl3 expressing the different Flt3 isoforms was obtained as previously described. 27 In short, the membrane proximal region of a mutated flt3 receptor sequence as well as wild-type human flt3 derived from the Oci-AML5 cell line (nt1567-2077) was substitutionally introduced into the sequence of murine flt3. These sequences were expressed in 32D cells under the control of the 5ЈLTR of the MoMuSV, derived from pLXSN (Clontech, Palo Alto, CA, USA). Polyclonal cell lines were used for the described experiments.
The complete coding sequence of flt3 from a patient with ITD mutation was amplified by reverse transcriptasepolymerase chain reaction (RT-PCR) using Pfu DNA polymerase. The sense primer was 5Ј-GATCGATATGCCGGCG TTGGCGCGCGACGCG-3Ј and the antisense primer was 5Ј-CACTAGTCTACGAATCTTCGACCTGAGCCTG-3Ј. The products were introduced into the pCRII-TOPO Vector (Invitrogen) and, after confirmation of the sequences by DNA sequencing, subcloned into the expression vector pAL 27 using the BamHI and PstI restriction sites. Ten micrograms of plasmid DNA of either plasmid and 1 g pMAM/BSD (Kaken Pharmaceutical, Japan) were cotransfected into 32Dcl3 cells by electroporation. Cells were selected with 15 g/ml blasticidin (Invitrogen) in IL-3-supplemented culture. Polyclonal cell lines were used for further experiments.
MTT proliferation assay
Inhibitor effects on proliferation of TEL-Flt3-or HA-TEL-Flt3-transfected BA/F3 cells, parental BA/F3 cells and EOL-1 cells were measured by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) proliferation assay (Roche Diagnostics, Mannheim, Germany) according to the instructions of the manufacturer. In brief, 10 5 cells per well were grown in 96 well plates at 37°C/5% CO 2 in the presence of different concentrations of inhibitors (or dimethylsulfoxide (DMSO) as a control, final DMSO concentration: 0.1%) up to 3 days. At the desired timepoint, 10 l MTT solution was added per well. After incubation for 4 h at 37°C/5% CO 2 , 100 l solubilization buffer per well was added and incubated Leukemia overnight. Formazan production was measured by a microplate reader at 570 nm. For treatment with IL-3, the cytokine was added at 3 ng/ml.
3H thymidine incorporation assays
A total of 1 × 10 4 32D cells was IL-3-and serum-starved (0.5% FCS) for 12 h. Subsequently, cells were placed in 200 l medium including 10% FCS and supplemented with either 50 ng/ml FL, 10 ng/ml IL-3 or no cytokine as indicated. Thirty minutes prior to addition of the cytokines and serum, tyrosine kinase inhibitors were added at the indicated concentration. DMSO was added in control experiments at the highest concentration used in the assay, with no effect. After 24 h incubation at 37°C, 1 Ci 3 H thymidine was added to each well and cells were incubated for an additional 8 h. Cells were harvested on glass fiber filters, and ␤-emission of the bound DNA was analyzed by a scintillation counter. Experiments were repeated at least three times. Each data point represents the mean of three wells.
Radiation-induced apoptosis
A total of 2.5 × 10 5 cells were IL-3 and serum starved for 3 h, placed in 24-well plates and exposed to 5 Gy ␥-irradiation. Prior to irradiation, the tyrosine kinase inhibitors were added at the indicated concentration. DMSO was added in control experiments at the highest concentration used in the assay, with no effect. Immediately after irradiation, cells were supplemented with FL (100 ng/ml), IL-3 (1 ng/ml) or no factor, as indicated. Cell viability was analyzed using the Annexin-V assay. Cells staining negatively for both Annexin-V and propidium iodide were counted as viable cells.
Measurement of protein phosphorylation in cellular assays
To measure Flt3 or c-Kit autophosphorylation, EOL-1 cells or CHRF cells, respectively, were starved in serum-free medium in the absence or presence of inhibitors for 4 h (5 × 10 6 cells per 15 ml tube (NUNC)) at 37°C and then stimulated with 100 ng/ml FL or 40 ng/ml SCF, respectively, for 5 min at room temperature. Thereafter the cells were sedimented (4 min, 300 g), washed twice with 10 ml ice-cold PBS and extracted with 100 l lysis buffer containing 20 mM Hepes, pH 7.5, 150 mM NaCl, 1% Triton X-100, 10 mM EDTA, 2 mM EGTA, 10 mM sodium pyrophosphate, 50 mM NaF, 5 g/ml leupeptin, 20 M zinc acteate, 2 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride (PMSF), 0.3 M aprotinin and 1 mM benzamidine. The cleared lysates were subjected to immunoprecipitation with anti-Flt3 or anti-c-Kit antibodies (1 g per sample), respectively, and the immunoprecipitates were separated by SDS-PAGE. Receptor phosphorylation was detected by immunoblotting with anti-phosphotyrosine antibodies. cFms phosphorylation was measured similarly but in COS-7 cells, transiently transfected with a human c-Fms expression plasmid. Starved cells were stimulated with 100 ng/ml CSF-1 for 5 min at room temperature, extracted and receptor phosphorylation was detected by immunoblotting of whole cell lysate aliquots.
For p-Akt immunoblots, equal protein amounts of whole cell lysates were used.
In vitro Flt3 assays
The chimeric hPDGF␤R-mFlt3 protein was transiently overexpressed in 293 cells using the calcium phosphate method. Fifteen g of the hPDGF␤R-mFlt3 expression plasmid was cotransfected with 5 g of an expression plasmid for the protein-tyrosine phosphatase SHP-1 per 10 cm dish. Cotransfection with SHP-1 reduced constitutive autophosphorylation of the chimeric receptor in the cells and enabled efficient autophosphorylation of the purified protein in vitro. Purification of the hPDGF␤R-mFlt3 and in vitro autophosphorylation were performed similarly as described previously. 39 The transfected cells were washed once with ice-cold PBS and subsequently lysed (1 ml lysis buffer per 10 cm dish). The cell extract was then incubated at 4°C with wheat germ agglutinin agarose (Pharmacia Biotech, Freiburg, Germany, 1 ml beads per cell extract of 5-10 dishes), equilibrated with 40 mM Hepes, pH 7.4, 0.5 M NaCl, 0.05% Triton X100, 10% glycerol, 1 mM EGTA and 1 mM DTT (WGA buffer) with end-over-end rotation for 90 min. The mixture was placed into a column, the beads were washed with 5 ml WGA buffer and then eluted with 5 ml 0.3 M N-acetylglucosamine in WGA buffer. The eluate was diluted 1:1 with buffer A (20 mM Tris-HCl, pH 7.5, 100 mM KCl, 10 mM ␤-mercaptoethanol, 10% glycerol, 10 mM imidazole) and incubated with 1 ml Ni-NTA agarose beads (Qiagen, Heidelberg, Germany) equilibrated in the same buffer at 4°C with end-over-end rotation for 1 h. The beads were washed twice with buffer A, once with 20 mM Tris-HCl pH 7.5, 1 M KCl, 10 mM ␤-mercaptoethanol, 10% glycerol and again once with buffer A. Elution was done in batches by adding 0.6 ml 100 mM imidazole in buffer A, incubating the beads on ice with occasional shaking for several minutes and collecting the supernatant. According to silver staining, this preparation was homogenous and could be stored for extended times at −80°C with 0.5% BSA added. For in vitro autophosphorylation, 20 l of the hPDGF␤R-mFlt3 preparation was incubated in the presence or absence of inhibitors on ice for 15 min, then for a further 20 min with PDGF-BB (2 g/ml). Kinase buffer (5 mM MnCl 2 , 50 mM Hepes, pH 7.4, 0.1 mM sodium orthovanadate; final concentrations) and ␥ 32 P ATP (2.5 Ci per reaction) were then added and the mixture incubated at 30°C for 20 min. The reaction was stopped by addition of SDS-PAGE sample buffer and autophosphorylation was analyzed by SDS-PAGE and autoradiography. Similar conditions were employed for measuring the autophosphorylation activity of HA-TEL-Flt3, immunoprecipitated with anti-HA antibodies from extracts of HA-TEL-Flt3-expressing BA/F3 cells.
A fusion protein of GST and the hFlt3 cytoplasmic domain was expressed in Sf9 cells and purified by standard techniques. In vitro kinase assays with this protein were carried out as described previously, except that kinase activity was assayed as autophosphorylation at a kinase concentration of approximately 100 ng/ml.
38
Results and discussion
Bis(1H-2-indolyl)-1-methanones, a class of compounds previously found to inhibit PDGF receptor kinase activity, were tested for their efficacy towards Flt3. Selected compounds were screened for inhibition of Flt3-dependent cell growth. For these assays we used BA/F3 cells whose growth is driven by the constitutively active Flt3 variants TEL-Flt3 or HA-TELFlt3. 28 The most potent derivatives in this assay were D-64406 and D-65476 (Figure 1 ). In the presence of IL-3 the compounds affected proliferation of Flt3-expressing cells and also of parental BA/F3 cells to a much lesser extent, indicating selectivity for inhibition of Flt3-vs IL-3-dependent proliferation (Table 1, Figure 2 ). Similar findings were obtained with 32D cells transfected with either wild-type Flt3 or Flt3 variant harboring the activating ITD mutation (Figure 3 ). Cells grown in the presence of FL were inhibited by the compounds whereas cells grown in the presence of IL-3 were clearly less sensitive to inhibition. However, at high inhibitor concentrations cell growth is also inhibited in the presence of IL-3, suggesting the possible existence of additional targets of the compounds in the pathway of IL-3-stimulated proliferation. The small differences in the extent of rescue by IL-3 of the inhibition in Flt3 wild-type compared to Flt3-ITD-transformed cells reflect most likely experimental variations rather than a mechanistic difference. Interestingly, cells with the Flt3-ITD variant appeared somewhat more susceptible to inhibition than those harboring wild-type Flt3. The latter cells also grow in the absence of FL and growth is further enhanced in the presence of FL. 27 However, for the dose dependence of inhibition by bis(1H-2-indolyl)-1-methanones the presence or absence of FL had little effect. The increased sensitivity of Flt3-ITD cells to the bis(1H- 2-indolyl)-1-methanone kinase inhibitors is reminiscent of the recent finding that acute myeloid leukemia blasts harboring Flt3 ITD mutations exhibit enhanced sensitivity to the kinase inhibitor AG1295. 33 Growth inhibition of the cell lines with transfected Flt3 variants is expected to occur through inhibition of Flt3 activity by the bis(1H-2-indolyl)-1-methanones. As shown with BA/F3 cells expressing HA-TEL-Flt3, this is indeed the case. When such cells were treated with D-65476, autophosphorylation of the HA-TEL-Flt3 is greatly reduced at 0.3 M of the inhibitor and completely abrogated at higher concentrations (Figure 4) .
We also tested the effect of bis(1H-2-indolyl)-1-methanones on tumor cells with endogenous Flt3. EOL-1 human eosinophilic leukemia cells overexpress Flt3 and also express FL. 40 Thus, growth of these cells is believed to be at least partly driven by autocrine activation of Flt3. D-64406 and D-65476 potently inhibited the growth of EOL-1 cells (Table 1 ). In contrast, the Philadelphia chromosome-positive cell line K562, which depends on the activity of the Bcr-Abl fusion protein kinase for proliferation, is completely refractory to bis(1H-2-indolyl)-1-methanone treatment (Table 1) .
FL-stimulated autophosphorylation of Flt3 in EOL-1 cells is potently inhibited by bis(1H-2-indolyl)-1-methanones as shown for D-65476 in Figure 5a . Also, FL-stimulated activation of the Akt/PKB-kinase (Figure 5b ) is inhibited by D-65476 in these cells with similar dose-response characteristics.
Leukemia
We were also interested in the susceptibility of other hematopoietic receptor tyrosine kinases from the class III family to bis(1H-2-indolyl)-1-methanones. Interestingly, SCF-stimulated c-Kit autophosphorylation in CHRF cells and CSF-1-stimulated c-Fms autophosphorylation in transfected COS-7 cells were less susceptible or even refractory, respectively, to D-65476 treatment (Figure 5c and d) . These data further support the relatively narrow selectivity of the bis(1H-2-indolyl)-1-methanones. PDGF receptors (␣ and ␤-subtype) 38 and Flt3 are susceptible kinases whereas little sensitivity was found for a panel of tyrosine and serine-threonine kinases including FGF receptor-1, c-Kit, EGF receptor, insulin and IGF1 receptors and different PKC isoforms. 38 We also wished to know whether bis(1H-2-indolyl)-1-methanones act by direct inhibition of Flt3. In order to test this, we developed two different protocols for isolation of recombinant Flt3. A GST-fusion protein of the Flt3 cytoplasmic domain was expressed in Sf9 cells and purified by standard methods. Kinase activity was assayed as autophosphorylation. This Flt3 kinase preparation was inhibited by both D-64406 and D-65476 (Table 1) . In an alternative assay, a Cterminally His-tagged PDGFR-Flt3 fusion protein was purified from transiently transfected 293 cells and subjected to autophosphorylation assays. Again, the isolated Flt3 kinase is inhibited by the bis(1H-2-indolyl)-1-methanones ( Figure 6 ). Also, immunoprecipitated HA-TEL-Flt3 is inhibited in an immunocomplex kinase assay ( Figure 6 ). The IC 50 values for D-64406 in the in vitro assays were two-to five-fold higher than those detected in the cell-based assays (Table 1) . A larger discrepancy was observed for D-65476, which exhibited greatly reduced efficacy in the in vitro assays compared to cellular effects. The reasons for these quantitative differences are unknown. It is possible that D-65476 undergoes conversion to a more active derivative in cells. However, the in vitro experiments demonstrate clearly that bis(1H-2-indolyl)-1-methanones can directly inhibit Flt3.
To further evaluate the possible usefulness of bis(1H-2-indolyl)-1-methanone compounds for targeting activated Flt3, we investigated the combined efficacy of radiation and bis(1H-2-indolyl)-1-methanones on the survival of 32D cells transfected with Flt3. Expression of Flt3 with ITD is known to confer resistance to radiation-induced apoptosis. 27 This is also seen in the experiments shown in Figure 7 . 32D cells trans- Bis(1H-2-indolyl)-1-methanone kinase inhibitors suppress Flt3-mediated resistance to radiation-induced apoptosis. 32D cells transfected with the indicated Flt3 constructs were starved for 3 h and exposed to 5 Gy ␥-irradiation. Thirty minutes prior to irradiation, cells were exposed to the indicated concentrations of the tyrosine kinase inhibitors D-65476 or D-64406. Immediately after irradiation, cytokines were added (FL: 50 ng/ml, IL-3: 10 ng/ml). Analysis for viability was performed 24 h after irradiation. Cells which were Annexin-V and propidium iodide negative were counted as viable cells. Viability was calculated as a percentage of viable cells before irradiation. Viability before irradiation was Ͼ85% in all experiments. Flt3-WT, cells expressing murine Flt3 wild-type; mFlt3-ITD, cells expressing murine Flt3 harboring human ITD sequence; hFLT3-ITD, cells expressing the human Flt3-ITD. seen in Flt3 wild-type cells treated with FL. Importantly, IL-3 treatment completely rescues both types of cells from radiation-induced apoptosis even in the presence of high inhibitor concentrations. This finding again supports the selectivity of bis(1H-2-indolyl)-1-methanone treatment for inhibition of Flt3-dependent signal transduction.
In conclusion, the bis(1H-2-indolyl)-1-methanone derivatives D-65476 and D-64406 used in the present study are potent and selective inhibitors of the class III type receptor tyrosine kinase Flt3. The compounds appear more potent than AG1295 and AG1296, quinoxalin tyrphostins previously shown to inhibit Flt3. 32 Thus, bis(1H-2-indolyl)-1-methanones present a promising class of compounds to be developed to treat Flt3-dependent types of leukemia.
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